APA

Wijburg M. T., Witte B. I., Vennegoor A., Roosendaal S. D., Sanchez E., Liu Y., Martins Jarnalo C. O., Uitdehaag B. M., Barkhof F., Killestein J. & Wattjes M. P. (20170606). MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. : Journal of neurology, neurosurgery, and psychiatry.

Chicago

Wijburg Martijn T, Witte Birgit I, Vennegoor Anke, Roosendaal Stefan D, Sanchez Esther, Liu Yaou, Martins Jarnalo Carine O, Uitdehaag Bernard Mj, Barkhof Frederik, Killestein Joep and Wattjes Mike P. 20170606. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. : Journal of neurology, neurosurgery, and psychiatry.

Harvard

Wijburg M. T., Witte B. I., Vennegoor A., Roosendaal S. D., Sanchez E., Liu Y., Martins Jarnalo C. O., Uitdehaag B. M., Barkhof F., Killestein J. and Wattjes M. P. (20170606). MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. : Journal of neurology, neurosurgery, and psychiatry.

MLA

Wijburg Martijn T, Witte Birgit I, Vennegoor Anke, Roosendaal Stefan D, Sanchez Esther, Liu Yaou, Martins Jarnalo Carine O, Uitdehaag Bernard Mj, Barkhof Frederik, Killestein Joep and Wattjes Mike P. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. : Journal of neurology, neurosurgery, and psychiatry. 20170606.